CareDx

CareDx is a healthcare company focused on precision diagnostics and connected services for complex care. Its website describes its work across transplant, cell therapy, and specialty oncology, combining molecular testing with workflow software, patient support, and pharmacy services. The company presents these offerings as tools to help care teams identify risk, manage clinical complexity, and maintain patient support beyond the clinic. CareDx serves both clinicians and patients. For clinicians, it says it delivers actionable insights through diagnostics, streamlined workflows, and communication. For patients, it describes an integrated approach that includes support solutions intended to inform clinical decisions and help improve outcomes. Its stated mission is to create life-changing solutions that enable patients to thrive. The company reports a global workforce of 650 employees and 180 commercial employees supporting customers and patients. Its website identifies Brisbane and Stockholm as headquarters locations. It also describes work on patient advocacy, health equity, public health, and sustainability, including programs related to transplant education, waitlisting, medication adherence, and organ donation. John Hanna is identified on the company site as President and CEO. CareDx is presented as an active business; the supplied evidence does not establish its founding date, founder, ownership, or listing status.

The supplied evidence does not provide CareDx’s founding date, founder, or early corporate history, so those details cannot be established here. The company’s current positioning, as described on its website, centers on precision medicine and connected services for transplant, cell therapy, and specialty oncology. Its stated offering spans molecular diagnostics, workflow tools, patient support, and pharmacy services, reflecting an approach that combines clinical testing with operational and patient-facing support. CareDx describes its work as serving both clinicians and patients: diagnostic insights and streamlined workflows for care teams, and support solutions intended to help patients navigate care. The company also highlights research, digital innovation, patient advocacy, health equity, and sustainability. Its corporate site identifies John Hanna as President and CEO and reports a global workforce, with Brisbane and Stockholm named as headquarters locations. The available evidence describes the company as active but does not document dated corporate milestones, ownership changes, or listing details.

A precision-medicine and connected-care provider for complex transplant, cell therapy, and specialty oncology journeys, combining diagnostics with digital workflows and patient-facing services.

• Molecular diagnostics and monitoring

  Molecular testing and monitoring presented for complex care, including transplant-related care.

• Workflow tools and software

  Digital tools intended to help specialty care teams manage workflows and care complexity.

• Patient services and transplant pharmacy support

  Patient support and pharmacy services that extend CareDx's offering beyond diagnostic testing.

• 2020

  Natera files patent infringement suit against CareDx

  Natera announced that it filed a lawsuit against CareDx alleging infringement of Natera's U.S. Patent 10,526,658. The announcement presents Natera's allegation; it does not state that a court has reached any determination on the claim. This note records the filing of the suit as reported and attributes the infringement allegation to Natera.

  Source

Read more

• 2021.01.07

  Reported2021.01.07

  CareDx and IDbyDNA announce exclusive partnership[7]CareDx与IDbyDNA宣布独家合作finance.yahoo.com

  CareDx and IDbyDNA announced an exclusive partnership to develop and commercialize AlloID, an infectious disease testing solution tailored to organ transplant donors and recipients.

• 2020.03.17

  Reported2020.03.17

  CareDx launches RemoTraC home-based monitoring service[8]CareDx 推出 RemoTraC 居家监测服务biospace.com

  CareDx announced the launch of RemoTraC, a remote home-based blood draw solution for transplant patients. The service uses mobile phlebotomy for AlloSure and AlloMap surveillance tests and other standard monitoring tests.

• 2020.01.13

  Reported2020.01.13

  Natera files patent infringement suit against CareDx[6]Natera files patent infringement suit against CareDxprnewswire.com

  Natera said it filed suit against CareDx alleging infringement of Natera's U.S. Patent 10,526,658. The article reports the allegation, not a court determination.

Read more

1. 1CareDx | Precision Diagnostics in Transplant and Specialty Oncologycaredx.com
2. 2Corporate Responsibility | CareDxcaredx.com
3. 3Compliance and Ethics | CareDx Corporate Standardscaredx.com
4. 4About CareDx | Purpose, Leadership, Innovationcaredx.com
5. 5CareDx, Incwikidata.org
6. 6Natera files patent infringement suit against CareDxprnewswire.com
7. 7CareDx与IDbyDNA宣布独家合作finance.yahoo.com
8. 8CareDx 推出 RemoTraC 居家监测服务biospace.com